drugset / Trial / NCT06570473
Feasibility Trial for a Right Ventricular Failure Platform Trial
Phase 2
Recruiting
30 enrolled
University of Alberta
Accelerating Clinical Trials Consortium · collabCanadian Heart Function Alliance · collabOttawa Heart Institute Research Corporation · collabTeam PHenomenal Hope · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of the CRAVE feasibility trial is to assess the feasibility of conducting a larger CRAVE platform trial by performing a randomized trial of 30 participants with pulmonary hypertension and right ventricular dysfunction, comparing empagliflozin or ranolazine plus standard of care to standard of care alone.
Timeline
- Start
- 2025-07-15
- Primary completion
- 2026-08
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 10 mg | Oral |
| Subject | Ranolazine | Small molecule | 500 mg | Oral |
| Subject | Ranolazine | Small molecule | 1000 mg | Oral |